Cutaneous Metastasis
A 68-year-old man presented with a sudden-onset, 2.5 × 2-cm, rock-hard, erythematous, nontender nodule on the right side of the chest. A dense mat of telangiectases surrounded the solitary lesion. The remainder of the cutaneous examination was unremarkable.
A 68-year-old man presented with a sudden-onset, 2.5 × 2-cm, rock-hard, erythematous, nontender nodule on the right side of the chest. A dense mat of telangiectases surrounded the solitary lesion. The remainder of the cutaneous examination was unremarkable.
The differential diagnosis of the lesion, which was clearly a tumor, included both primary cutaneous neoplasia (particularly squamous cell carcinoma, nodular amelanotic melanoma, and various sarcomas) and cutaneous metastasis from an occult focus of an internal carcinoma. A biopsy revealed pleomorphic cells arranged in glandlike tubular structures embedded in a richly vascular stroma; this finding strongly suggested a renal cell carcinoma.
A thorough systemic evaluation revealed a primary tumor that involved the right kidney and asymptomatic hepatic and osseous metastases. The patient declined therapy and was lost to follow-up.
About 2% to 5% of all visceral malignancies result in cutaneous metastases.1 Of particular note: the first sign of renal cell and bronchogenic carcinomas may well be skin metastases.
REFERENCE:1. Rosen T. Cutaneous metastases. Med Clin North Am. 1980;64:885-900.
Lebrikizumab Demonstrates Efficacy, Safety in Patients With Skin of Color With AD
June 11th 2025RAD 2025. Lebrikizumab improved skin clearance, itch, and pigmentation in patients with skin of color and atopic dermatitis, with strong safety data through 24 weeks, according to late-breaking data.
